VX-702

Catalog No.S6005

VX-702 Chemical Structure

Molecular Weight(MW): 404.3

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 110 In stock
USD 370 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Reduction of IL-10 expression due to p38 inhibition is observed also in CpG-stimulated B cells and using VX-702. B cells were pre-treated with 10 uM of VX-702 for 1 h and stimulated with LPS or CpG for 24 or 48 h. Bar graphs indicate mean (±SEM) IL-10 concentrations at 48 h from n = 4 (LPS) and n = 3 (CpG) experiments. Significant differences against the no inhibitor condition were calculated using a paired Student's t-test and indicated as follows: *p < 0.05, ***p < 0.001.

    Mol Immunol 2014 62(2), 266-76. VX-702 purchased from Selleck.

     Bone marrow derived macrophages were pre-treated with the indicated concentrations of VX702 for 1h prior to LPS treatment (100 ng/ml).  TNF-a production was analyzed 24h later.

    Lee lay hoon from National University of Singapore. VX-702 purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4nFS2lvcGmkaYTpc44hd2ZiaIXtZY4hUE:SLU[yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xOTV2MzFOwG0> NYPwNm9TW0GQR1XS
human NCI-H720 cell Mk\BS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn;yTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEeyNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODF4OEKg{txO M4LydXNCVkeHUh?=
JVM-2 cell NF;NZ2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYDJcohq[mm2aX;uJI9nKGi3bXHuJGpXVS1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6wPFMh|ryP NX21fYljW0GQR1XS
human NCI-H69 cell NVfDXXdpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFG0OJlKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB7OUSxJO69VQ>? MX7TRW5ITVJ?
human BV-173 cell NXLGOmUxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXjJcohq[mm2aX;uJI9nKGi3bXHuJGJXNTF5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVE{QDZizszN MX3TRW5ITVJ?
human KU812 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGPVTZBKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjR6ODFOwG0> NX:2c2F2W0GQR1XS
human DU-145 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGDhblNKdmirYnn0bY9vKG:oIHj1cYFvKESXLUG0OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTR3NUSg{txO MojkV2FPT0WU
KARPAS-45 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYPlZ|lCUW6qaXLpeIlwdiCxZjDoeY1idiCNQWLQRXMuPDViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG0PFI3KM7:TR?= NF3pb5lUSU6JRWK=
human AGS cell NWjHNZdmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYfJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUWyOVEh|ryP NF\lfnZUSU6JRWK=
human MOLT-13 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4HxPWlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV7OEGg{txO MW\TRW5ITVJ?
human NCI-H209 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkC5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPzV6IN88US=> MnPRV2FPT0WU
human CTV-1 cell NETm[o1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2SyfmlvcGmkaYTpc44hd2ZiaIXtZY4hS1SYLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE5Ozh7IN88US=> NEHsO|dUSU6JRWK=
LU-139 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlrzTY5pcWKrdHnvckBw\iCqdX3hckBNXS1zM{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE6PDN3IN88US=> MXnTRW5ITVJ?
ML-2 cell MlvTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIXRNYJKdmirYnn0bY9vKG:oIHj1cYFvKE2OLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIzPjZzIN88US=> M1H0TXNCVkeHUh?=
human K5 cell NWjt[FhmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXnJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{MkmxO{DPxE1? M33PZXNCVkeHUh?=
human SBC-1 cell MkHXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXPJ[YJuUW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN4MjFOwG0> MYrTRW5ITVJ?
human COR-L88 cell M2j2O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mom4TY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzR6IN88US=> M3jp[XNCVkeHUh?=
human KY821 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUDoWYVWUW6qaXLpeIlwdiCxZjDoeY1idiCNWUiyNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzl4MEOg{txO MWXTRW5ITVJ?
human HCC2218 cell NHzjOIVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH6zfGVKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{KyNVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR7N{K4JO69VQ>? NXzKO5RyW0GQR1XS
human ECC10 cell Mlf1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXvYR25iUW6qaXLpeIlwdiCxZjDoeY1idiCHQ1OxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjV|OEmg{txO NULYfoV5W0GQR1XS
human EW-3 cell MnXyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4e3fWlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOlY3OTFizszN Mn3NV2FPT0WU
human EW-18 cell Mn3IS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MonSTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|Q3PzlizszN Mm\xV2FPT0WU
human UACC-257 cell MnfHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXTJcohq[mm2aX;uJI9nKGi3bXHuJHVCS0NvMkW3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zODN{NjFOwG0> M2m3[3NCVkeHUh?=
human G-361 cell MoX4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NE\KTGlKdmirYnn0bY9vKG:oIHj1cYFvKEdvM{[xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41QTVzOTFOwG0> M3O4ZnNCVkeHUh?=
human HMV-II cell M2TTemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{HDN2lvcGmkaYTpc44hd2ZiaIXtZY4hUE2YLVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44PzF6NDFOwG0> MUTTRW5ITVJ?
human DEL cell NHLSeJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4C1dWlvcGmkaYTpc44hd2ZiaIXtZY4hTEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yNFcxPCEQvF2= NWOzb4llW0GQR1XS
human IGROV-1 cell NG\KSGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3PtfWlvcGmkaYTpc44hd2ZiaIXtZY4hUUeUT2[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDNzOEig{txO MmLDV2FPT0WU
human SK-OV-3 cell MonvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3Xve2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPjF4OUeg{txO M{HBTHNCVkeHUh?=
human LAMA-84 cell Mkm1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnNdndKdmirYnn0bY9vKG:oIHj1cYFvKEyDTVGtPFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjdzMki0JO69VQ>? NX7UUHJGW0GQR1XS
human NCI-H510A cell MoG0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYfKWmZoUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUyOEFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmyOVI3KM7:TR?= M3nEUnNCVkeHUh?=
human CP66-MEL cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKGi3bXHuJGNRPjZvTVXMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk46OzV3OTFOwG0> Ml3IV2FPT0WU
human HAL-01 cell M4nWdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkH5TY5pcWKrdHnvckBw\iCqdX3hckBJSUxvMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI4QTF6IN88US=> NU\ZRodkW0GQR1XS
human RS4-11 cell  MlLBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHrYfYxKdmirYnn0bY9vKG:oIHj1cYFvKFKVND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzB3N{Og{txO NXvkXFdyW0GQR1XS
human RPMI-8226 cell NV;DO3VvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVGycmk3UW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVgzOjZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkiyN|c3KM7:TR?= NFXPdmRUSU6JRWK=
human NCI-H82 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2\uSWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDl|MEWg{txO MWLTRW5ITVJ?
human NY cells M3jlTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWqxRoxPUW6qaXLpeIlwdiCxZjDoeY1idiCQWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNlc3OzdizszN NGT1PFBUSU6JRWK=
human MDA-MB-361 cell NGLRUHFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUDJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR|MUW4JO69VQ>? MnrrV2FPT0WU
human MOLT-4 cell NHi0cm1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXvUPFF{UW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7MUmzJO69VQ>? M4TWdHNCVkeHUh?=
human DU-4475 cell NFG3V|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYnJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTR2N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlA2PTZ3IN88US=> NFLRRmlUSU6JRWK=
human ESS-1 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1f1RmlvcGmkaYTpc44hd2ZiaIXtZY4hTVOVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI6OTd7IN88US=> Mkn3V2FPT0WU
human NCI-H1299 cell Ml;WS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4DWVGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNlk6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53M{CzN{DPxE1? M1HPOXNCVkeHUh?=
human COLO-684 cell Mo\uS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXLJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42QDF4NTFOwG0> M4jj[3NCVkeHUh?=
human MV-4-11 cell M1nDcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF2we41KdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjdzMUm5JO69VQ>? NI\wNpdUSU6JRWK=
human D-542MG cell NXjkfFhvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIr2d4JKdmirYnn0bY9vKG:oIHj1cYFvKERvNUSyUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjN7MkeyJO69VQ>? MknOV2FPT0WU
human A4-Fuk cell NEnpZ|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFm1O3pKdmirYnn0bY9vKG:oIHj1cYFvKEF2LV\1b{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPDN4NkKg{txO M1PMWHNCVkeHUh?=
human HL-60 cell NYPLcot2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHH3SIVKdmirYnn0bY9vKG:oIHj1cYFvKEiOLU[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{42OjJzMjFOwG0> M{S0bnNCVkeHUh?=
human NCI-H526 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmDrTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEWyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPTl6MEGg{txO NIjYTFZUSU6JRWK=
human L-363 cell NGjZbmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYPJcohq[mm2aX;uJI9nKGi3bXHuJGwuOzZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz63PVI2OiEQvF2= NHr4[pdUSU6JRWK=
human A388 cell M4DOTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWDJcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkiwN|g1KM7:TR?= M{LZN3NCVkeHUh?=
human MS-1 MmLlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEHLbFRKdmirYnn0bY9vKG:oIHj1cYFvKE2VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlg{PDZ3IN88US=> MVLTRW5ITVJ?
human JAR cell NFvWW2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnHrTY5pcWKrdHnvckBw\iCqdX3hckBLSVJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Lki0PVI{KM7:TR?= M3TMOnNCVkeHUh?=
human TI-73 cell NEHZZ4hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUfJcohq[mm2aX;uJI9nKGi3bXHuJHRKNTd|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OD6wOlIzKM7:TR?= NYH2cWxVW0GQR1XS
human CTB-1 cell NF;ncWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4jnU2lvcGmkaYTpc44hd2ZiaIXtZY4hS1SELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlE4QDJ3IN88US=> M{XhfnNCVkeHUh?=
human SK-NEP-1 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYXZXGRqUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OSXAuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzLkOwN|gh|ryP M{jpVHNCVkeHUh?=
human HT-29 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFS2XXFKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvQTFzMTFOwG0> MW\TRW5ITVJ?
human NCI-H1092 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3yxVmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNFkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTRwM{G4JO69VQ>? MYnTRW5ITVJ?
human KMOE-2 cell MlHJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFPoVpBKdmirYnn0bY9vKG:oIHj1cYFvKEuPT1WtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjZzN{ig{txO NEXEZ3hUSU6JRWK=
human EM-2 cell NEKzdpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVrJcohq[mm2aX;uJI9nKGi3bXHuJGVONTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNT6yPFQyKM7:TR?= MXPTRW5ITVJ?
human RT-112 cell MmTCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYPJcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1MlM6QDRizszN MWHTRW5ITVJ?
human DB cell MnftS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEX5bZhKdmirYnn0bY9vKG:oIHj1cYFvKESEIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuPFUyOyEQvF2= NHjtbZlUSU6JRWK=
human NCI-H1770 cell M1GwVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkLWTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3O|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigQ>? M3\V[HNCVkeHUh?=
human CAL-54 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVfJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG2Mlc{KM7:TR?= MWjTRW5ITVJ?
human NB14 cell M3f1Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWTJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNz62N|k2KM7:TR?= MVvTRW5ITVJ?
human RPMI-7951 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml76TY5pcWKrdHnvckBw\iCqdX3hckBTWE2LLUe5OVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yQS5zN{izJO69VQ>? NXThUGQ4W0GQR1XS
human T47D cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGjzVWtKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4zOjR|IN88US=> MXPTRW5ITVJ?
human A549 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NET5dZJKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4zQDFzIN88US=> NYC0Uo5RW0GQR1XS
human A2780 cell NXrQSJIxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoTSTY5pcWKrdHnvckBw\iCqdX3hckBCOjd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKxMlgzOjVizszN Mnq3V2FPT0WU
human SK-MEL-24 cell MoPoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M17HemlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzNwMEOxNUDPxE1? MlnnV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID